PharmaCyte Biotech Inc
PMCB
$1.220 0.83%
Exchange: NASDAQ | Sector: Healthcare | Industry: Biotechnology
Q1 2026
Published: Sep 15, 2025

Earnings Highlights

  • EPS of $-1.23 decreased by 823.5% from previous year
  • Net income of -8.36M
  • "Transcript not provided." -
PMCB
Company PMCB

Executive Summary

PharmaCyte Biotech reported QQ1 2026 with no reported revenue and a net loss of 8.36 million USD, driven predominantly by a substantial non-operating expense of 7.51 million and a negative total other income/expenses of 7.51 million. Operating activity generated a modest cash burn (CFO of -1.99 million) and the company ends the quarter with cash and equivalents of 13.18 million USD. The balance sheet shows a sizable portfolio of long-term investments (24.45 million) and intangible assets (1.55 million), with total assets of 45.11 million and stockholdersโ€™ equity of 43.59 million, but retains a meaningful accumulated deficit and a notable non-operating liability structure reflected in the reported metrics. The near-term liquidity remains robust relative to current liabilities, but the path to profitability remains highly dependent on external financing or meaningful scientific milestones. Management commentary (where available) would be pivotal to gauge readiness for potential partnerships, licensing opportunities, or readouts from the CellinaBox platform when and if clinical or preclinical catalysts arise. Absent concrete revenue or binding licensing deals, the core valuation driver remains the companyโ€™s ability to secure future funding and monetize its asset base through strategic collaborations or portfolio monetization.

Key Performance Indicators

Operating Income
Increasing
-848.31K
QoQ: 11.66% | YoY: 73.21%
Net Income
Decreasing
-8.36M
QoQ: -174.52% | YoY: -720.65%
EPS
Decreasing
-1.23
QoQ: -179.55% | YoY: -823.53%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q1 2026 0.00 -1.23 +0.0% View
Q3 2025 0.00 -0.44 +0.0% View
Q2 2025 0.00 -0.39 +0.0% View
Q1 2025 0.00 1.90 +0.0% View
Q4 2024 0.00 0.17 +0.0% View